{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:58:54Z","timestamp":1785416334977,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction. Increasing evidence has suggested inflammation is involved in the pathogenesis of MG, but whether it is the cause or a downstream effect remains unclear. In this study, a two-sample Mendelian randomization (TSMR) analysis was performed to explore the causal relationship between 91 circulating inflammatory cytokines and MG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>In this study, the data of 91 circulating inflammatory cytokines from 4824 Europeans and the largest GWAS database of MG (1873 patients and 36370 controls) were used to screen instrumental variables (IVs). Inverse variance weighting (IVW), Bayesian weighted MR (BWMR), MR-Egger regression, weighted median (WM), simple mode and weighted mode were used to evaluate the association between MG and inflammatory cytokines. The MR-Egger intercept test and Cochran\u2019s Q test were used to test the pleiotropy and heterogeneity of IVs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result<\/jats:title>\n            <jats:p>Our results showed that adenosine deaminase (ADA) and CD40 Ligand\u200c (CD40L) are positively associated with the risk of MG (OR\u2009=\u20091.16, 95%CI: 1.00-1.33, <jats:italic>P<\/jats:italic>\u2009=\u20090.041; OR\u2009=\u20091.20, 95%CI: 1.02\u20131.40, <jats:italic>P<\/jats:italic>\u2009=\u20090.025), while interleukin-1-alpha (IL-1\u03b1), glial-cell-line-derived neurotrophic factor (GDNF), Osteoprotegerin (OPG) and tumor necrosis factor-beta (TNF-\u03b2) are negatively associated with the risk of MG (OR\u2009=\u20090.80, 95% CI: 0.64\u2009~\u20090.99, <jats:italic>P<\/jats:italic>\u2009=\u20090.042; OR\u2009=\u20090.74, 95%CI:0.58\u2009~\u20090.0.96, <jats:italic>P<\/jats:italic>\u2009=\u20090.022; OR\u2009=\u20090.76, 95% CI: 0.61\u2009~\u20090.94, <jats:italic>P<\/jats:italic>\u2009=\u20090.013; OR\u2009=\u20090.76, 95% CI: 0.61\u2009~\u20090.94, <jats:italic>P<\/jats:italic>\u2009=\u20090.012; OR\u2009=\u20090.80, 95% CI: 0.68\u2009~\u20090.93, <jats:italic>P<\/jats:italic>\u2009=\u20090.006). In addition, genetically predicted MG affected the expression of seven cytokines. Sensitivity analysis showed no horizontal pleiotropy and significant heterogeneity of all results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our results provided promising clues for the treatment of MG. We evaluated the association between inflammatory cytokines and the disease by genetic informatics approach, which may help to better understand the underlying mechanisms of MG.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12883-025-04271-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:02:30Z","timestamp":1751360550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Circulating inflammatory cytokines and the risk of myasthenia gravis: a bidirectional Mendelian randomization study"],"prefix":"10.1186","volume":"25","author":[{"given":"Boyang","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xusheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"26","key":"4271_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"4271_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia Gravis. J Med Life. 2021;14(1):7\u201316.","journal-title":"J Med Life"},{"key":"4271_CR3","doi-asserted-by":"publisher","first-page":"1110499","DOI":"10.3389\/fimmu.2023.1110499","volume":"14","author":"R Huda","year":"2023","unstructured":"Huda R. Inflammation and autoimmune myasthenia Gravis. Front Immunol. 2023;14:1110499.","journal-title":"Front Immunol"},{"issue":"15","key":"4271_CR4","doi-asserted-by":"publisher","first-page":"e2004433","DOI":"10.1002\/advs.202004433","volume":"8","author":"C Liu","year":"2021","unstructured":"Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: from clinical significance to quantification. Adv Sci (Weinh). 2021;8(15):e2004433.","journal-title":"Adv Sci (Weinh)"},{"key":"4271_CR5","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3389\/fimmu.2017.01785","volume":"8","author":"Z Wang","year":"2017","unstructured":"Wang Z, Yan Y. Immunopathogenesis in myasthenia Gravis and neuromyelitis Optica. Front Immunol. 2017;8:1785.","journal-title":"Front Immunol"},{"issue":"9","key":"4271_CR6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1212\/WNL.41.9.1497","volume":"41","author":"RA Maselli","year":"1991","unstructured":"Maselli RA, Richman DP, Wollmann RL. Inflammation at the neuromuscular junction in myasthenia Gravis. Neurology. 1991;41(9):1497\u2013504.","journal-title":"Neurology"},{"key":"4271_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1749-6632.1993.tb22873.x","volume":"681","author":"S Cohen-Kaminsky","year":"1993","unstructured":"Cohen-Kaminsky S, Delattre RM, Devergne O, Klingel-Schmitt I, Emilie D, Galanaud P, et al. High IL-6 gene expression and production by cultured human thymic epithelial cells from patients with myasthenia Gravis. Ann N Y Acad Sci. 1993;681:97\u20139.","journal-title":"Ann N Y Acad Sci"},{"key":"4271_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.016","volume":"52","author":"P Cufi","year":"2014","unstructured":"Cufi P, Dragin N, Ruhlmann N, Weiss JM, Fadel E, Serraf A, et al. Central role of interferon-beta in thymic events leading to myasthenia Gravis. J Autoimmun. 2014;52:44\u201352.","journal-title":"J Autoimmun"},{"issue":"1","key":"4271_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/nyas.13519","volume":"1412","author":"MA Cron","year":"2018","unstructured":"Cron MA, Maillard S, Villegas J, Truffault F, Sudres M, Dragin N, et al. Thymus involvement in early-onset myasthenia Gravis. Ann N Y Acad Sci. 2018;1412(1):137\u201345.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"4271_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","volume":"12","author":"P Cavalcante","year":"2013","unstructured":"Cavalcante P, Cufi P, Mantegazza R, Berrih-Aknin S, Bernasconi P, Le Panse R. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun Rev. 2013;12(9):863\u201374.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"4271_CR11","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1111\/jnc.16138","volume":"168","author":"Y Weng","year":"2024","unstructured":"Weng Y, Zhu J, Li S, Wang Y, Lin S, Xie W, et al. Dynamic changes of peripheral inflammatory markers link with disease severity and predict short-term poor outcome of myasthenia Gravis. J Neurochem. 2024;168(9):2751\u201361.","journal-title":"J Neurochem"},{"issue":"5","key":"4271_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/1745691610383505","volume":"5","author":"GD Smith","year":"2010","unstructured":"Smith GD. Mendelian randomization for strengthening causal inference in observational studies: application to gene \u00d7 environment interactions. Perspect Psychol Sci. 2010;5(5):527\u201345.","journal-title":"Perspect Psychol Sci"},{"issue":"11","key":"4271_CR13","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1681\/ASN.2016010098","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula P, Del Greco MF, Pattaro C, K\u00f6ttgen A. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol. 2016;27(11):3253\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"4271_CR14","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. Jama. 2017;318(19):1925\u20136.","journal-title":"Mendelian Randomization Jama"},{"issue":"9","key":"4271_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41590-023-01588-w","volume":"24","author":"JH Zhao","year":"2023","unstructured":"Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman \u00c5K, Kalnapenkis A, et al. Genetics of Circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol. 2023;24(9):1540\u201351.","journal-title":"Nat Immunol"},{"key":"4271_CR16","doi-asserted-by":"crossref","unstructured":"Chia R, Saez-Atienzar S, Murphy N, Chi\u00f2 A, Blauwendraat C, Roda RH et al. Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci U S A. 2022;119(5).","DOI":"10.1073\/pnas.2206754119"},{"issue":"12","key":"4271_CR17","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/aje\/kwr026","volume":"173","author":"TM Palmer","year":"2011","unstructured":"Palmer TM, Sterne JA, Harbord RM, Lawlor DA, Sheehan NA, Meng S, et al. Instrumental variable Estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am J Epidemiol. 2011;173(12):1392\u2013403.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"4271_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377\u201389.","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"4271_CR19","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1093\/bioinformatics\/btz749","volume":"36","author":"J Zhao","year":"2020","unstructured":"Zhao J, Ming J, Hu X, Chen G, Liu J, Yang C. Bayesian weighted Mendelian randomization for causal inference based on summary statistics. Bioinformatics. 2020;36(5):1501\u20138.","journal-title":"Bioinformatics"},{"issue":"5","key":"4271_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal Pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"4271_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12883-020-01885-z","volume":"20","author":"QX Zhang","year":"2020","unstructured":"Zhang QX, Li Y, Jiang SM, Zhang LJ, Yi M, Wang J, et al. Increased serum IL-36\u03b3 levels are associated with disease severity in myasthenia Gravis patients. BMC Neurol. 2020;20(1):307.","journal-title":"BMC Neurol"},{"key":"4271_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jocn.2019.02.012","volume":"63","author":"Z Wang","year":"2019","unstructured":"Wang Z, Wang W, Chen Y, Xu S, Wei D, Huang X. Elevated expression of interleukin-33 in myasthenia Gravis patients. J Clin Neurosci. 2019;63:32\u20136.","journal-title":"J Clin Neurosci"},{"issue":"7","key":"4271_CR23","doi-asserted-by":"publisher","first-page":"7550","DOI":"10.18632\/oncotarget.6885","volume":"7","author":"JM Weiss","year":"2016","unstructured":"Weiss JM, Robinet M, Aricha R, Cufi P, Villeret B, Lantner F, et al. Novel CXCL13 Transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia Gravis. Oncotarget. 2016;7(7):7550\u201362.","journal-title":"Oncotarget"},{"issue":"6","key":"4271_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2174\/138945012800564095","volume":"13","author":"L Antonioli","year":"2012","unstructured":"Antonioli L, Colucci R, La Motta C, Tuccori M, Awwad O, Da Settimo F, et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Targets. 2012;13(6):842\u201362.","journal-title":"Curr Drug Targets"},{"key":"4271_CR25","doi-asserted-by":"crossref","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11).","DOI":"10.3390\/jcm10112235"},{"issue":"1\u20132","key":"4271_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/0022-510X(90)90030-Q","volume":"100","author":"S Chiba","year":"1990","unstructured":"Chiba S, Matsumoto H, Motoi Y, Miyano N, Kashiwagi M. High serum adenosine deaminase activity and its correlation with lymphocyte subsets in myasthenia Gravis. J Neurol Sci. 1990;100(1\u20132):174\u20137.","journal-title":"J Neurol Sci"},{"issue":"5","key":"4271_CR27","first-page":"586","volume":"35","author":"G Masi","year":"2022","unstructured":"Masi G, O\u2019Connor KC. Novel pathophysiological insights in autoimmune myasthenia Gravis. Curr Opin Neurol. 2022;35(5):586\u201396.","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"4271_CR28","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.4049\/jimmunol.166.11.6893","volume":"166","author":"SH Im","year":"2001","unstructured":"Im SH, Barchan D, Maiti PK, Fuchs S, Souroujon MC. Blockade of CD40 ligand suppresses chronic experimental myasthenia Gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol. 2001;166(11):6893\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"4271_CR29","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1038\/s41467-021-24347-7","volume":"12","author":"L van Hooren","year":"2021","unstructured":"van Hooren L, Vaccaro A, Ramachandran M, Vazaios K, Libard S, van de Walle T, et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint Blockade in glioma. Nat Commun. 2021;12(1):4127.","journal-title":"Nat Commun"},{"key":"4271_CR30","doi-asserted-by":"crossref","unstructured":"Ots HD, Tracz JA, Vinokuroff KE, Musto AE. CD40-CD40L in neurological disease. Int J Mol Sci. 2022;23(8).","DOI":"10.3390\/ijms23084115"},{"issue":"4","key":"4271_CR31","doi-asserted-by":"publisher","first-page":"e0123546","DOI":"10.1371\/journal.pone.0123546","volume":"10","author":"V Yilmaz","year":"2015","unstructured":"Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, et al. Differential cytokine changes in patients with myasthenia Gravis with antibodies against achr and musk. PLoS ONE. 2015;10(4):e0123546.","journal-title":"PLoS ONE"},{"issue":"11","key":"4271_CR32","doi-asserted-by":"publisher","first-page":"102668","DOI":"10.1016\/j.autrev.2020.102668","volume":"19","author":"M Ramanujam","year":"2020","unstructured":"Ramanujam M, Steffgen J, Visvanathan S, Mohan C, Fine JS, Putterman C. Phoenix from the flames: rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmun Rev. 2020;19(11):102668.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"4271_CR33","first-page":"449","volume":"34","author":"K Utsugisawa","year":"1994","unstructured":"Utsugisawa K, Yamagata M, Saitho K, Kawamorita A, Tohgi H. [In situ expression of IL-1 beta and IL-2 mRNA in thymuses from patients with myasthenia gravis]. Rinsho Shinkeigaku. 1994;34(5):449\u201353.","journal-title":"Rinsho Shinkeigaku"},{"issue":"5","key":"4271_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/BF00918185","volume":"11","author":"C Aime","year":"1991","unstructured":"Aime C, Cohen-Kaminsky S, Berrih-Aknin S. In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia Gravis. J Clin Immunol. 1991;11(5):268\u201378.","journal-title":"J Clin Immunol"},{"issue":"10","key":"4271_CR35","first-page":"660","volume":"38","author":"X Liu","year":"1999","unstructured":"Liu X, Li Z, Liu Y, Tang L, You G. [Changes of the interleukin-1 in dysfunction of central nervous system in myasthenia gravis]. Zhonghua Nei Ke Za Zhi. 1999;38(10):660\u20132.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"1","key":"4271_CR36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/imr.12615","volume":"281","author":"A Malik","year":"2018","unstructured":"Malik A, Kanneganti TD. Function and regulation of IL-1\u03b1 in inflammatory diseases and cancer. Immunol Rev. 2018;281(1):124\u201337.","journal-title":"Immunol Rev"},{"issue":"5","key":"4271_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<543::AID-MUS2>3.0.CO;2-9","volume":"20","author":"GX Zhang","year":"1997","unstructured":"Zhang GX, Navikas V, Link H. Cytokines and the pathogenesis of myasthenia Gravis. Muscle Nerve. 1997;20(5):543\u201351.","journal-title":"Muscle Nerve"},{"issue":"1\u20132","key":"4271_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0165-5728(01)00473-8","volume":"122","author":"P Christadoss","year":"2002","unstructured":"Christadoss P, Goluszko E. Treatment of experimental autoimmune myasthenia Gravis with Recombinant human tumor necrosis factor receptor Fc protein. J Neuroimmunol. 2002;122(1\u20132):186\u201390.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"4271_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0165-5728(98)00144-1","volume":"90","author":"MG Manz","year":"1998","unstructured":"Manz MG, Melms A, Sommer N, M\u00fcller CA. Myasthenia Gravis and tumor necrosis factor beta polymorphisms: linkage disequilibrium but no association beyond HLA-B8. J Neuroimmunol. 1998;90(2):187\u201391.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"4271_CR40","first-page":"98","volume":"27","author":"P Huang","year":"2023","unstructured":"Huang P. The relationship between serum iron levels and AChR-Ab and IL-6 in patients with myasthenia Gravis. Eur Rev Med Pharmacol Sci. 2023;27(1):98\u2013102.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4271_CR41","doi-asserted-by":"publisher","first-page":"577634","DOI":"10.1016\/j.jneuroim.2021.577634","volume":"358","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Akamine H, Kojima Y, Ozawa Y, Yasuda M, Onishi Y, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia Gravis. J Neuroimmunol. 2021;358:577634.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"4271_CR42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mus.22070","volume":"44","author":"JC Roche","year":"2011","unstructured":"Roche JC, Capablo JL, Larrad L, Gervas-Arruga J, Ara JR, S\u00e1nchez A, et al. Increased serum interleukin-17 levels in patients with myasthenia Gravis. Muscle Nerve. 2011;44(2):278\u201380.","journal-title":"Muscle Nerve"},{"issue":"6","key":"4271_CR43","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","volume":"27","author":"DI Jonsson","year":"2017","unstructured":"Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of Tocilizumab in myasthenia Gravis refractory to rituximab. Neuromuscul Disord. 2017;27(6):565\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"4271_CR44","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","volume":"171","author":"E T\u00fcz\u00fcn","year":"2003","unstructured":"T\u00fcz\u00fcn E, Scott BG, Goluszko E, Higgs S, Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia Gravis. J Immunol. 2003;171(7):3847\u201354.","journal-title":"J Immunol"},{"issue":"3","key":"4271_CR45","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.4049\/jimmunol.175.3.2018","volume":"175","author":"H Yang","year":"2005","unstructured":"Yang H, T\u00fcz\u00fcn E, Alagappan D, Yu X, Scott BG, Ischenko A, et al. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia Gravis is associated with suppressed serum Proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J Immunol. 2005;175(3):2018\u201325.","journal-title":"J Immunol"},{"issue":"4","key":"4271_CR46","first-page":"625","volume":"34","author":"JM Kremer","year":"2016","unstructured":"Kremer JM, Blanco R, Halland AM, Brzosko M, Burgos-Vargas R, Mela CM, et al. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with Tocilizumab in a randomised trial. Clin Exp Rheumatol. 2016;34(4):625\u201333.","journal-title":"Clin Exp Rheumatol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04271-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:05:21Z","timestamp":1751364321000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04271-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4271"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04271-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original GWAS data, the studies on MG and 91 inflammatory cytokines were all approved by institutional review boards with informed consent from all patients. In this study, we only summarized the data and did not require additional participant ethical consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}